Health Trials

About this trial

This clinical study aims to determine whether taking two different doses of collagen-derived peptides for three months improves facial skin barrier integrity in women with dry, sensitive skin, compared with a placebo.

Eligibility criteria

Qualifiers

Participant having signed an Informed Consent Form (ICF);

Healthy female Participant aged 45 to 70 years inclusive not followed by a healthcare practitioner for any skin disease;

Participant with phototype II to IV according to the Fitzpatrick classification;

Participant with dry skin measured on the cheeks (Tewameter, TEWL >15g/m²/h (skin barrier integrity) on back of the cheekbone)

Disqualifiers

Participant with a BMI ≤17 or ≥30 kg/cm²;

Participant with any uncontrolled diseases such as diabetes, hypertension, hyperthyroidism or hypothyroidism;

Presenting or having a history of eating disorder (e.g. anorexia, food allergy) or gastrointestinal malabsorption such as celiac disease, Crohn's disease, lactose intolerance;

Participant with an history of sleeve or bypass;

Trial design

Treatments tested in this trial

  • Investigational Product 1
  • Investigational Product 2
  • Placebo

Treatment groups

75 Participants
are divided into 3 treatment groups

Locations

1
CPCAD - Centre Pharmacologie Clinique Appliqué à la Dermatologie, CHU Nice06200, Nice France

Sponsors and collaborators

Centre de Pharmacologie Clinique Applique a la Dermatologie

Lead sponsor

Rousselot BVBA

Collaborator

Source ClinicalTrials.gov